These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 22191317

  • 1. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S, Rakić S, Nikolić L, Jovicić B, Stajević M, Vukomanović V, Kosutić J.
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ.
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L, Cui L, Wei JP, Li GP, Qi GX, Hao YM, Wang WZ, Li HM, Liu J, Jiang DJ, Zhang YD.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
    Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
    Lancet; 2002 Jul 20; 360(9328):196-202. PubMed ID: 12133653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov 20; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G, Kremastinos DT.
    Am J Cardiol; 2008 Nov 01; 102(9):1225-9. PubMed ID: 18940297
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ, Domínguez Rodríguez A.
    Am J Cardiovasc Drugs; 2006 Nov 01; 6(2):69-75. PubMed ID: 16555860
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G.
    Eur J Heart Fail; 2010 Apr 01; 12(4):404-10. PubMed ID: 20335355
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E, Moosbauer W, Pinter M, Mair R, Tulzer G.
    Pediatr Crit Care Med; 2007 Jan 01; 8(1):61-3. PubMed ID: 17149153
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.